Cohen Martin (Director) purchases 100,000 shares of CNS across 4 transactions totaling $5,982,411.83 at blended average $59.82.
Martin Cohen acquired 100,000 shares in four separate transactions between November 18-20, 2025, increasing his holdings from 849.2K shares to 949.2K shares (+11.8%), with a total cash outlay of $5,982,411.83. The purchases occurred at a blended average price of $59.82, while the stock currently trades at $59.47, only marginally below the transaction prices. This substantial acquisition—executed across multiple trading days at relatively stable prices near current levels—occurred against a backdrop where CNS has declined 44.2% from its 52-week high of $106.60 and is down 15.9% over the past 30 days and 22.0% over 90 days. The company fundamentals remain solid, with trailing-quarter net income of $41.7M on revenue of $141.7M and a P/E of 18.47 on a $3.0B market cap, though annual revenue growth has moderated to +5.7%. The scale and timing of this director-level accumulation merit investor attention in light of the stock's recent weakness and the substantial capital commitment.